Oncternal Therapeutics Inc (ONCT)

NASDAQ
1.540
+0.721(+88.08%)
After Hours
1.470
-0.070(-4.545%)
- Real-time Data
  • Volume:
    20,761,027
  • Day's Range:
    0.947 - 1.610
  • 52 wk Range:
    0.690 - 5.870

ONCT Overview

Prev. Close
0.819
Day's Range
0.947-1.61
Revenue
4.32M
Open
0.951
52 wk Range
0.69-5.87
EPS
-0.71
Volume
20,761,027
Market Cap
74.14M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
630,734
P/E Ratio
-
Beta
1.7
1-Year Change
-85.22%
Shares Outstanding
49,429,054
Next Earnings Date
Aug 11, 2022
What is your sentiment on GTX Inc?
or
Market is currently closed. Voting is open during market hours.

Oncternal Therapeutics Inc News

Oncternal Therapeutics Inc Analysis

Oncternal Therapeutics Inc Company Profile

Oncternal Therapeutics Inc Company Profile

Employees
28

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. Its product candidates include Zilovertamab, ONCT-808, ONCT-534 and ONCT-216. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1), a growth factor receptor that is expressed on many tumors and that activates pathways to increased tumor proliferation, invasiveness and drug resistance, and bind to a specific functionally important epitope of ROR1. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyBuySell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
  • 250m usd company? This should be bought at 3 billion.
    0
    • Excellent data readout! Prepare for a buyout in 2021. HOLD and add some more if you can.
      0
      • test
        0
        • This one could be yummy
          0
          • But, I'm surprised NOW.
            0
            • Won't be surprised if ONCT hit $4 before end of January 2021.
              0
              • WHAT'S UP. Why dropped so much AH?😅
                0
                • why drop ?
                  0
                  • wow, pending defence deal.
                    1
                    • they way overvalued for a research company. they got no revenue.
                      0